bispecific
Showing 1 - 25 of 569
Advanced Solid Tumors Trial in Guangzhou (MR001)
Not yet recruiting
- Advanced Solid Tumors
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Nov 12, 2023
Cancer Trial in Tuebingen (Bispecific antibodies (bsAB))
Available
- Cancer
- Bispecific antibodies (bsAB)
-
Tuebingen, Baden-Wuerttemberg, GermanyUniversity Hospital Tuebingen
Nov 2, 2022
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Colorectal Cancer Trial (Administration of CC-3)
Not yet recruiting
- Colorectal Cancer
- Administration of CC-3
- (no location specified)
Aug 11, 2023
Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)
Terminated
- Neuroblastoma
- +2 more
- Humanized 3F8 Bispecific Antibody
- Blood draw
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 11, 2022
Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)
Not yet recruiting
- Advanced Prostate Cancer
-
Lyon, France
- +2 more
Oct 18, 2023
Peripheral T-cell Lymphoma Trial in Beijing (AK104)
Terminated
- Peripheral T-cell Lymphoma
- AK104
-
Beijing, Beiing, ChinaBeijing Cancer Hospital
Oct 17, 2022
Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- AK104
- Lenvatinib
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Oct 17, 2022
Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)
Active, not recruiting
- Hepatocellular Carcinoma
- AK104 lenvatinib
- AK104
-
Hangzhou, Zhejiang, ChinaThe first affilited hospital zhejiang university school of medci
Oct 17, 2022
HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)
Not yet recruiting
- HIV-1-infection
- ART
- +2 more
-
Mbeya, TanzaniaNational Institute for Medical Research-Mbeya Medical Resarch Ce
Jun 6, 2023
Malignant Tumor Trial in Shanghai (PM8002)
Recruiting
- Malignant Neoplasm
-
Shanghai, Shanghai, ChinaShanghai Orient Hospital
Jun 25, 2023
SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)
Not yet recruiting
- SCLC,Extensive Stage
- AK104 IV infusion;Chiauranib oral
-
Changchun, Jilin, ChinaJilin Province Cancer Hospital
Aug 16, 2022
HER2-positive Recurrent or Metastatic Malignant Solid Tumor Trial in Zhengzhou (Recombinant Humanized Bispecific Monoclonal
Recruiting
- HER2-positive Recurrent or Metastatic Malignant Solid Tumor
- Recombinant Humanized Bispecific Monoclonal Antibody MBS301
-
Zhengzhou, ChinaHenan Cancer Hospital
Nov 9, 2022
Primary Sjogren's Syndrome Trial in Palo Alto (tibulizumab (LY3090106))
Withdrawn
- Primary Sjogren's Syndrome
- tibulizumab (LY3090106)
-
Palo Alto, CaliforniaStanford University
Jan 12, 2022
Locally Advanced or Metastatic Solid Tumors, Squamous-cell NSCLC Trial in Shanghai, Xuzhou (HLX35)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- Squamous-cell Non-small Cell Lung Cancer
-
Shanghai, China
- +1 more
Jun 28, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS))
Not yet recruiting
- Hepatocellular Carcinoma
- Cadonilimab
- transjugular intrahepatic portosystemic shunt (TIPS)
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 30, 2023
Solid Tumor, Adult Trial in Guangzhou (AK112)
Active, not recruiting
- Solid Tumor, Adult
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 8, 2022